Subsequent Events - Additional Information (Details) - USD ($)	Dec. 04, 2024	Nov. 25, 2024	Oct. 09, 2024	Sep. 30, 2024	Mar. 13, 2024	Dec. 31, 2023	Jul. 31, 2023	Apr. 10, 2023
Subsequent Event [Line Items]
Common stock, par value				$ 0.0001		$ 0.0001
Exercise price					$ 8.1		$ 3.5	$ 7.5
Maximum
Subsequent Event [Line Items]
Exercise price							$ 7.5
Subsequent Event
Subsequent Event [Line Items]
Proceeds from notes and purchaser warrants	$ 750,000
Common stock, par value		$ 0.0001
Floor Price		$ 1
Minimum gross proceeds from subsequent financing transaction		$ 2,500,000
Term (years)		5 years
Percentage of cash fee equal to aggregate proceeds		7.00%
Percentage of exercise price equal to offering price		125.00%
Percentage of non-accountable expense fee		1.00%
Initial retainer fee		$ 25,000
Annual interest rate		8.00%
Line of credit increase in interest rate during period in event of default		10.00%
Exercise price		$ 2.85
Subsequent Event | Maximum
Subsequent Event [Line Items]
Notes and purchaser warrants principal amount		$ 1,000,000
Reimbursement of legal expenses		$ 75,000
Sequence LifeScience, Inc [Member] | Subsequent Event
Subsequent Event [Line Items]
Consideration paid for assets			$ 5,500,000
Upfront payment			1,000,000
Monthly milestone payments			4,000,000
Prior payment to related party			$ 500,000
Net sales percentage			20.00%